Jazz Pharmaceuticals plc — Director's Dealing 2013

Aug 13, 2013

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2013-08-09

Reporting Person: Tobias Jeffrey K (EVP, Research & Dev and CMO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2013-08-09	Ordinary Shares	F	3288	$80.88	Disposed	44405	Direct
2013-08-12	Ordinary Shares	M	7500	$46.83	Acquired	51905	Direct
2013-08-12	Ordinary Shares	S	7500	$80.77	Disposed	44405	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2013-08-12	Nonstatutory Stock Option (right to buy)	$46.83	M	7500	Disposed	2022-08-08	Ordinary Shares (7500)	Direct

Footnotes

F1: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.

F2: Includes 193 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 31, 2013.

F3: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F4: This nonstatutory stock option is part of an option granted on August 9, 2012 that consisted of the nonstatutory stock option exercisable for 61,640 ordinary shares and an incentive stock option exercisable for 8,540 ordinary shares and has a vesting schedule of one fourth vested on August 9, 2013 and the remainder vesting in 36 equal monthly installments thereafter.

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.22 to $81.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.